13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q2 2019. See the latest, Q3 2026 →

Reported value

$11.05B

−7.2% on the quarter before

Positions

32

1 new, 4 sold out

Top 10

70.2%

of the value

Est. gain

+$52.5M

on stocks held all quarter

Est. return

+0.5%

on those stocks since Q1 2019

Filed

Aug 13, 2019

On SEC EDGAR ↗

Positions as of Jun 30, 2019, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2019. Striped tiles are options.

Liberty Global Plc10%
Viasat Inc10%
Fox Corp9.1%
Ebay Inc8.6%
Cheniere Energy Inc6.6%
Allergan Plc5.6%
Bristol Myers Squibb Co5.3%
Qorvo5.2%
Pg&E Corp5.1%
Cbs Corp New4.5%
8 others3.6%
Mckesson Corp3.2%
Synchrony Finl2.9%
Tesla2.7%
Colony Cap Inc New2.2%
Univar Inc1.9%
Fox Corp1.9%
Liberty Global Plc1.8%
Amerisourcebergen Corp1.7%
Takeda Pharmaceutical Co Ltd1.5%
Antero Res Corp1.4%
Theravance Biopharma Inc1.4%
Nexstar Media Group Inc1.3%
Atara Biotherapeutics Inc1.3%
Akebia Therapeutics Inc1.1%

Largest buys

Since Q1 2019, sized at quarter-end prices.

  1. Bristol Myers Squibb Co~$408.1MAdded, 1.6% → 5.3% of the portfolio+9,000,000 shares
  2. Xpo Logistics Inc~$86.7MNew, 0.0% → 0.8% of the portfolio+1,500,000 shares
  3. Liberty Global Plc~$75.5MAdded, 8.0% → 10.1% of the portfolio+2,844,679 shares
  4. Cbs Corp New~$72.8MAdded, 3.4% → 4.5% of the portfolio+1,457,984 shares
  5. Liberty Global Plc~$67.0MAdded, 1.0% → 1.8% of the portfolio+2,483,500 shares
  6. Nexstar Media Group Inc~$40.2MAdded, 0.9% → 1.3% of the portfolio+397,755 shares
  7. Translate Bio Inc~$29.1MAdded, 0.5% → 1.0% of the portfolio+2,352,941 shares
  8. Atara Biotherapeutics Inc~$12.5MAdded, 2.1% → 1.3% of the portfolio+619,481 shares
  9. Trilogy Metals Inc New~$1.7MAdded, 0.3% → 0.4% of the portfolio+590,610 shares

Largest sells

Since Q1 2019, sized at quarter-end prices.

  1. Celgene Corp~$377.4MSold out, 3.2% → 0.0% of the portfolio−4,000,000 shares
  2. Pioneer Nat Res Co~$304.8MSold out, 2.6% → 0.0% of the portfolio−2,001,814 shares
  3. Ebay Inc~$203.0MCut, 9.1% → 8.6% of the portfolio−5,140,000 shares
  4. Allergan Plc~$182.5MCut, 5.9% → 5.6% of the portfolio−1,090,146 shares
  5. Synchrony Finl~$173.4MCut, 3.8% → 2.9% of the portfolio−5,000,000 shares
  6. Cheniere Energy Inc~$133.1MCut, 7.2% → 6.6% of the portfolio−1,944,173 shares
  7. Qorvo~$127.1MCut, 6.4% → 5.2% of the portfolio−1,907,901 shares
  8. Sinclair Broadcast Group Inc~$126.5MCut, 0.9% → 0.3% of the portfolio−2,358,673 shares
  9. Walt Disney Company (The)~$44.3MSold out, 0.4% → 0.0% of the portfolio−399,151 shares
  10. Mckesson Corp~$29.6MCut, 2.8% → 3.2% of the portfolio−220,000 shares

Holdings

As of Jun 30, 2019; changes in shares since Mar 31, 2019.

Positions, sorted by share of the portfolio
HoldingValue
Liberty Global PlcSHS CL C · shares +7.3% · price +9.6%10.1%$1.11B+$90.7M
Viasat IncCOM · shares 0% · price +4.3%10.0%$1.11B+$45.6M
Fox CorpCL A COM · shares 0% · price −0.2%9.1%$1.00B−$1.9M
Ebay IncCOM · shares −18% · price +6.4%8.6%$953.8M+$57.0M
Cheniere Energy IncCOM NEW · shares −15% · price +0.1%6.6%$730.6M+$960,738
Allergan PlcSHS · shares −23% · price +14.4%5.6%$616.1M+$77.3M
Bristol Myers Squibb CoCOM · shares +225% · price −4.9%5.3%$589.5M−$9.4M
QorvoCOM · shares −18% · price −7.1%5.2%$578.3M−$44.4M
Pg&E CorpCOM · shares 0% · price +28.8%5.1%$561.5M+$125.4M
Cbs Corp NewCL B · shares +17% · price +5.0%4.5%$499.0M+$20.2M
Mckesson CorpCOM · shares −7.8% · price +14.8%3.2%$348.7M+$45.0M
Synchrony FinlCOM · shares −35% · price +8.7%2.9%$321.1M+$25.7M
TeslaNOTE 2.375% 3/1 · shares 0% · price −10.0%2.7%$295.5M—
Colony Cap Inc NewCL A COM · shares 0% · price −6.0%2.2%$248.4M−$15.9M
Univar IncCOM · shares 0% · price −0.5%1.9%$209.4M−$1.1M
Fox CorpCL B COM · shares 0% · price +1.8%1.9%$207.5M+$3.7M
Liberty Global PlcSHS CL A · shares +50% · price +8.3%1.8%$200.8M+$10.3M
Amerisourcebergen CorpCOM · shares −7.9% · price +7.2%1.7%$188.8M+$12.7M
Takeda Pharmaceutical Co LtdSPONSORED ADS · shares −12% · price −13.1%1.5%$167.1M−$25.2M
Antero Res CorpCOM · shares 0% · price −37.4%1.4%$158.1M−$94.3M
Theravance Biopharma IncCOM · shares 0% · price −28.0%1.4%$152.0M−$59.0M
Nexstar Media Group IncCL A · shares +40% · price −6.8%1.3%$141.2M−$7.4M
Atara Biotherapeutics IncCOM · shares +9.7% · price −49.4%1.3%$140.8M−$125.3M
Akebia Therapeutics IncCOM · shares 0% · price −40.9%1.1%$118.4M−$82.0M
Translate Bio IncCOM · shares +36% · price +25.5%0.99%$109.4M+$16.3M
Total 32 positions100%$11.05B+$52.5M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q1 2019 to Q2 2019: 29 stocks held throughout, up $52.5M (+0.5%).

  1. Pg&E Corp+$125.4M+29%
  2. Liberty Global Plc+$90.7M+10%
  3. Allergan Plc+$77.3M+14%
  4. Ebay Inc+$57.0M+6%
  5. Viasat Inc+$45.6M+4%
  6. Qorvo−$44.4M−7%
  7. Theravance Biopharma Inc−$59.0M−28%
  8. Akebia Therapeutics Inc−$82.0M−41%
  9. Antero Res Corp−$94.3M−37%
  10. Atara Biotherapeutics Inc−$125.3M−49%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free